Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.

被引：14
|
作者：
Richardson, Paul G.
Rocafiguera, Albert Oriol
Beksac, Meral
Liberati, Anna Marina
Galli, Monica
Schjesvold, Fredrik
Lindsay, Jindriska
Weisel, Katja
White, Darell
Facon, Thierry
San-Miguel, Jesus
Sunami, Kazutaka
O'Gorman, Peter
Sonneveld, Pieter
Yu, Xin
Doerr, Thomas
Bensmaine, Amine
Zaki, Mohamed H.
Anderson, Kenneth Carl
Dimopoulos, Meletios A.
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
[2] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain
[3] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Barcelona, Spain
[4] Ankara Univ, Cebeci Yerleskesi, Dikimevi, Ankara, Turkey
[5] Univ Perugia, Terni, Perugia, Italy
[6] Osped Riuniti Bergamo, Osped Papa Giovanni XXIII, Ematologia, Bergamo, Italy
[7] Univ Oslo, Rikshosp, Postboks, Oslo, Norway
[8] East Kent Hosp Univ NHS Fdn Trust, Canterbury, Kent, England
[9] Univ Tubingen, Dept Hematol, Tubingen, Germany
[10] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[11] Hop Claude Huriez, Lille, France
[12] Clin Univ Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain
[13] Natl Hosp Org Okayama Med Ctr, Kitaku, Japan
[14] Univ Coll Dublin, Mater Misericordiae Univ Hosp, Dublin, Ireland
[15] Erasmus MC Canc Inst, Rotterdam, Netherlands
[16] Celgene Corp, Summit, NJ USA
[17] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8001
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).
    Vij, Ravi
    Richardson, Paul Gerard Guy
    Jagannath, Sundar
    Siegel, David Samuel DiCapua
    Baz, Rachid C.
    Srinivasan, Shankar
    Larkins, Gail
    Zaki, Mohamed H.
    Hussein, Mohamad A.
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Hofmeister, Craig C.
    Siegel, David
    Lonial, Sagar
    Laubach, Jacob P.
    Efebera, Yvonne A.
    Vesole, David H.
    Nooka, Ajay K.
    Rosenblatt, Jacalyn
    Raje, Noopur
    Zaki, Mohamed H.
    Hua, Ye
    Li, Yan
    Shah, Sheetal
    Wang, Jianming
    Anderson, Kenneth C.
    BLOOD, 2013, 122 (21)
  • [3] MM-005: A PHASE 1 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
    Richardson, P.
    Hofmeister, C.
    Siegel, D.
    Lonial, S.
    Laubach, J.
    Efebera, Y.
    Vesole, D.
    Nooka, A.
    Rosenblatt, J.
    Raje, N.
    Zaki, M.
    Hua, Y.
    Shah, S.
    Wang, J.
    Anderson, K.
    HAEMATOLOGICA, 2013, 98 : 97 - 98
  • [4] MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM)
    Richardson, Paul Gerard Guy
    Hofmeister, Craig C.
    Siegel, David Samuel DiCapua
    Lonial, Sagar
    Laubach, Jacob
    Efebera, Yvonne Adeduni
    Vesole, David H.
    Nooka, Ajay K.
    Rosenblatt, Jacalyn
    Raje, Noopur S.
    Zaki, Mohamed H.
    Hua, Ye
    Shah, Sheetal
    Wang, Jianming
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Pomalidomide plus Bortezomib plus Low-Dose Dexamethasone Vs Bortezomib plus Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial
    Dimopoulos, Meletios A.
    Weisel, Katja
    Moreau, Philippe
    Anderson, Larry
    White, Darrell J.
    San-Miguel, Jesus F.
    Sonneveld, Pieter
    Engelhardt, Monika
    Jenner, Matthew W.
    Corso, Alessandro
    Duerig, Jan
    Pavic, Michel
    Salomo, Morten
    Yu, Xin
    Tuong Vi Nguyen
    Bensmaine, Amine
    Peluso, Teresa
    Zaki, Mohamed
    Richardson, Paul
    BLOOD, 2018, 132
  • [6] Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
    Weisel, Katja
    Dimopoulos, Meletios
    Moreau, Philippe
    Yagci, Munci
    Larocca, Alessandra
    Kanate, Abraham S.
    Vural, Filiz
    Cascavilla, Nicola
    Basu, Supratik
    Johnson, Peter
    Byeff, Peter
    Hus, Marek
    Rodriguez-Otero, Paula
    Muelduer, Ercan
    Anttila, Pekka
    Hayden, Patrick J.
    Krauth, Maria-Theresa
    Lucio, Paulo
    Ben-Yehuda, Dina
    Mendeleeva, Larisa
    Guo, Shien
    Yu, Xin
    Grote, Lara
    Biyukov, Tsvetan
    Dhanasiri, Sujith
    Richardson, Paul
    LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 1850 - 1859
  • [7] OPTIMISMM: PHASE 3 STUDY OF POMALIDOMIDE, BORTEZOMIB, AND LOW DOSE OF DEXAMENTASONE VS. BORTEZOMIB AND LOW DOSE OF DEXAMETHASONE IN PATIENTS EXPOSED TO LENALIDOMIDE AFTER FIRST COLLECTION OF MULTIPLE MYELOMA
    Oriol, A.
    Richardson, P.
    Beksac, M.
    Liberati, A. M.
    Galli, M.
    Schjesvold, F.
    Lindsay, J.
    Weisel, K.
    White, D.
    Facon, T.
    Sunami, K.
    O'Gorman, P.
    Sonneveld, P.
    Robak, P.
    Semochkin, S.
    Schey, S.
    Yu, X.
    Doerr, T.
    Bensmaine, A.
    Biyukov, T.
    Caia, A.
    Zaki, M.
    Anderson, K.
    Dimopoulos, M.
    San Miguel, J.
    HAEMATOLOGICA, 2018, 103 : 90 - 91
  • [8] MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.
    Richardson, Paul G.
    Hofmeister, Craig
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Lonial, Sagar
    Laubach, Jacob
    Efebera, Yvonne Adeduni
    Vesole, David H.
    Nooka, Ajay K.
    Rosenblatt, Jacalyn
    Zaki, Mohamed H.
    Hua, Ye
    Li, Yan
    Shah, Sheetal
    Wang, Jianming
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
    P G Richardson
    C C Hofmeister
    N S Raje
    D S Siegel
    S Lonial
    J Laubach
    Y A Efebera
    D H Vesole
    A K Nooka
    J Rosenblatt
    D Doss
    M H Zaki
    A Bensmaine
    J Herring
    Y Li
    L Watkins
    M S Chen
    K C Anderson
    Leukemia, 2017, 31 : 2695 - 2701
  • [10] Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
    Richardson, P. G.
    Hofmeister, C. C.
    Raje, N. S.
    Siegel, D. S.
    Lonial, S.
    Laubach, J.
    Efebera, Y. A.
    Vesole, D. H.
    Nooka, A. K.
    Rosenblatt, J.
    Doss, D.
    Zaki, M. H.
    Bensmaine, A.
    Herring, J.
    Li, Y.
    Watkins, L.
    Chen, M. S.
    Anderson, K. C.
    LEUKEMIA, 2017, 31 (12) : 2695 - 2701
12345